GIDEON blog

Try it Free Latest Updates Video Tutorials
Subscribe , j

Archive for the ‘Reviews’ Category

INSURANCE RISK SOLUTION POWERED BY GIDEON DATA

man and woman health insurance

Read the full case study here

 

INCREASING EPIDEMIC FREQUENCY

There’s mounting evidence that the rates of infectious disease outbreaks have been increasing in frequency over the past few years. Perhaps even in the past two decades.

From the period of the Spanish flu pandemic in 1918 to the HIV/AIDS epidemic around 1981, there were only six pandemics on record. Approximately one per decade.

However, since the SARS outbreak of 2002, there has been an increased frequency of outbreaks.

The records show that SARS was quickly followed by several recurring and new outbreaks. AVIAN flu, MARBURG virus, SWINE flu, MERS, and EBOLA to name a few. 

COVID being the latest in the pattern of epidemics has grown into a pandemic. 

The world has gone from dealing with one serious outbreak every decade to dealing with a serious outbreak every couple of years. There have been 10 major outbreaks between 2002 and 2020.

 

IGNORING THE EVIDENCE 

Despite this growing trend, most companies didn’t consider epidemics a risk to their business.

The reason for this indifference to risk was simple. Pandemics that badly ravaged the world seemed isolated to the singular event of the Spanish flu. And this isolated event was about a century old. 

Added to this was the fact that epidemic insurance had little precedent as a product. And it is very complex to model and calculate. Coverage for business interruption due to communicable diseases was not typically offered by traditional insurance policies.

However, the situation now is that COVID-19 has changed all that. Organizations must prepare more carefully now given the recent impact of the pandemic. Knowing the historical records of the Spanish flu makes it prudent to prepare even more mindfully.

 

SEEING THE TREND 

Some insurers have taken notice of the increase in outbreaks of epidemics. 

Munich RE is a global provider of reinsurance, primary insurance, and insurance-related risk solutions. They took note of the increased rate of epidemic and pandemic events and started responding to the data. 

They decided to build a model that assesses epidemic risk. Building a model that allows for epidemic risk assessment is a very important part of developing insurance against that risk.

For this, they needed to have good data on infectious diseases over the past decades.

 

GIDEON DATA PAVES THE WAY TO A SUCCESSFUL MODEL

Munich RE employed GIDEON’s outbreak data in building its epidemic risk assessment model. It improved the accuracy and depth of their underlying data and the quality of their results.

Munich RE now offers Epidemic Risk Solutions to several industries including those that were hit the hardest by the COVID pandemic. 

GIDEON’s data paved the way for accurate models to assess risk and provide insurance coverage in the event of business interruption as a result of an epidemic.

This allows insurers to close a significant coverage gap that traditional insurance doesn’t.

With GIDEON’s disease outbreak data, insurers can make companies more resilient against business interruption due to an epidemic or pandemic. 

Companies have a stronger outlook now as epidemic and pandemic insurance has become a reality.

Read the full case study here

Join us on  Twitter, Facebook, and LinkedIn 

DIAGNOSIS TOOL OF CHOICE FOR 27 YEARS

A group of infectious diseases clinicians standing together
GIDEON is ideally suited to assist infectious diseases specialists

 

Read the full case study here

Medical Doctors have a serious enough job to do when caring for people’s health. But when their patients have recently been to other countries this may increase the complexity even more.

They must get information on the current state of infectious diseases in the country where the patient has been. With over 200 countries worldwide, doctors would have to be walking databases of infectious diseases.

SITUATIONS MEDICAL DOCTORS HAVE TO DEAL WITH

For example, now the flight restrictions due to COVID are being eased, it is reasonable to expect that experts will once again be called out to go to other countries and help with their knowledge.

If these experts fall ill when they return home, their doctors will have the job of getting information on infectious diseases in the countries they had just visited.

This can be complicated by many factors. Limited data, remote destinations, similar symptoms for multiple diseases, and numerous diseases in the given country, etc.

These factors may also lead to misdiagnoses and mistreatment.

In fact, in the case of an Israeli agricultural expert who fell ill when he returned from India he was misdiagnosed several times. And of course, he was then treated for the wrong disease.

However, when his symptoms were entered into GIDEON he was correctly diagnosed and treated. He was discharged in good health a week later.

QUICK & RELIABLE INFECTIOUS DISEASES DIAGNOSIS

This is just one of the many reasons why Dr. Jeffrey P. Gumprecht says that GIDEON is irreplaceable.

Nothing compares to GIDEON for diagnosing infectious diseases. Especially when a person’s health and life are at stake.

Dr. Gumprecht puts some details into the interactive tool. Details like when a patient traveled to a specific country, when they returned, their symptoms, and the organ systems involved. That’s all GIDEON needs to generate a Differential Diagnosis.

It also enables him to share information with other infectious disease specialists. He says it’s an amazingly valuable source of information, helping users to quickly reach a diagnosis.

GIDEON – BETTER THAN A LIBRARY

Dr. Gumprecht prefers it to the Library at New York University because he can get a full description of any infectious disease from GIDEON.

As great as libraries might be, none of the online library platforms have diagnostic tools. Going to the library at best extends the patient’s suffering. At worst it costs critical time a patient might not have.

That’s why Dr. Gumprecht thinks nothing compares to GIDEON. It’s invaluable to have a solution where all of the information on infectious diseases is available in one place. It eliminates the need to go through multiple review articles or separate websites.

GIDEON is very beneficial to the infectious disease fellows at Mt Sinai hospital where Dr. Gumprecht works.

Read the full case study here

And don’t forget to follow us on Twitter, Facebook, and LinkedIn. We’ve got exciting updates about our new interface!

Predicting the future with GIDEON data

Researcher and globe

Study the past if you would define the future.” – Confucius

If you want to study the past then GIDEON is a great place to do so. The question is, what would you do with over 750,000 data points, dating back to the 17th Century?

A team of researchers answered in a recent interview.

  • Tad Dallas, Assistant Professor at Louisiana State University
  • Colin J. Carlson, Assistant Research Professor at Georgetown University
  • Timothée Poisot, Assistant Professor at Université de Montréal

Idea

“The three of us have talked a lot about why predictions and ecology work or don’t work. We all share a lot of frustrations about where things fall short and how things get framed. We were having a conversation one day about what sort of minimum information is that you would need to know what the future looks like. Then Tad said: “I’m going to make a model with no predictors”. 

“It opened up this incredibly interesting question – What do we do with this model if it’s able to do predictions?”

How did the GIDEON data help with the study?

“We tried to make a completely predictor free model to just see if we can let the similarity of pathogen communities to inform prediction and see how this can influence the future.”

“The main question was to get a sense of what happens where and when it happens”, said Colin. “There isn’t any cohesive narrative about where outbreaks happen. We used the GIDEON data because we thought it might be the most complete thing there is.” 

The outcome

The team produced a research paper “Testing predictability of disease outbreaks with a simple model of pathogen biogeography“, published by The Royal Society in November 2019. It proved effective at making the disease outbreak predictions and was created using only GIDEON data. Impressive!

Predicting the future outbreaks - two diagrams

The value of data is only realized when it is put into context and made relevant to a particular problem or theory. You provide the context and the problem, and we’ll provide you with the data. How could GIDEON fuel your research?

Read the full case study here.

And don’t forget to follow us on Twitter, Facebook, and LinkedIn. We’ve got exciting updates about our new interface!

First alpha testing is complete!

Male doctor and female researcher testing GIDEON app

It takes a lot of courage to share a vision with users and critics, but the GIDEON team is in no short supply of that. In our recent alpha testing round, we opened up our brand new interface to medical experts from 25 countries who have very kindly shared their feedback on our successes and shortcomings.

What is alpha?

Quite simply, it is an early release of a major product upgrade. Our first alpha testing round focused on the display of our extensive database in a brand new ‘Explore’ module.

How did we do it?

We opted for feedback gathering mechanisms that support user independence and anonymity. This is different from a focus group, which is prone to leaving some opinions unheard. 

Our Trusted Advisors were a diverse bunch, consisting of 80+ medical professionals – from seasoned experts to students. Some testers have never seen our product before and others have been using GIDEON for years. 

The experience was scary, exciting, and necessary. We cannot thank our Trusted Advisors enough for their insight and valuable time spent exploring our new interface. The feedback has empowered a fruitful fine-tuning exercise, so if you are one of our testers – be sure to check out the implementation of your suggestions in the second alpha release!

Feedback

We are beside ourselves in anticipation of the release of the new interface (date to be confirmed soon) and based on the early feedback we know you are going to love it.

Here is a small sample of the comments we received:

This is a huge improvement. I very much like the general concept. The dark mode is also very nice.

Comprehensive.

Amazing work! So informative and pleasant to use.

Disease comparison is great. What a useful way to compare a differential!

I very much like the ‘fingerprint’ search concept for diseases.

The interface is easy to use.

Maps are amazing!!

Thoughtful, cohesive design.

Links to references are very useful.

What’s next?

We cannot wait to share this new experience with you all. It’s the same GIDEON data that you know and love, but like you’ve never seen before. 

If you are interested in a Bayes-powered Differential Diagnosis that uses one of the most impressive geographical medicine data sets in the world, sign up to test the all-new DIAGNOSE module. The second alpha is just around the corner!

Become our trusted advisor

Doody’s Collection reviews GIDEON

An in depth review and overview of GIDEON by Wladimir Labeikovsky is a feature article in the Doody’s Collection newsletter.

 

 

Review of GIDEON Guide to Antimicrobial Agents

Aug-2014-MT-Cover-headerThe Microbiology Society (formerly SGM) published a good review of the ebook, GIDEON Guide to Antimicrobial Agents, in Microbiology Today August 2014 issue.

Laura Bowater, the Editor, wrote:

I was able to find my way around the information quickly and easily … it is a comprehensive reference book that provides up-to-date accessible information. This format may particularly benefit those accessing it via a mobile phone. I can understand why it would work well in a clinical setting too.

It should be noted that the ebook is available separately from, and does not require a subscription to GIDEON.

Ebooks review in Clinical Infectious Diseases

GIDEON ebooks series review by Dr. Mary Wilson, Associate Professor of Global Health and Population, Harvard School of Public Health has appeared in the journal Clinical Infectious Diseases (CID 2010; 51(10):1227–1228).

Some excerpts:

[GIDEON] has now developed the GIDEON e-books system. This massive database, 411 books with 95,000 pages, presents material in 2 formats, by country and by infectious disease. Data are culled from papers published in journals, textbooks, Health Ministry publications, and materials from the Centers for Disease Control and Prevention and the World Health Organization.

The advantages of the system are many. It is an extraordinary database. It assembles a vast amount of material and makes it available in a consistent format.

GIDEON review in Travel Medicine and Infectious Disease

Dr. Stephen Toovey wrote a nice review of GIDEON in the Travel Medicine and Infectious Disease journal. He says “…there is no doubt that travel medicine practitioners, infectious disease physicians and microbiologists in need of a serious database will have to consider Gideon”

JAMA review of GIDEON

JAMA issue pictureA quote from the most recent review of GIDEON in JAMA (2005):
“…an intellectual tour de force for helping physicians quickly and successfully respond to the diagnostic and therapeutic problems of seeing patients with infectious illnesses that either are intrinsically complex or may have originated in unfamiliar, foreign settings. In times when exotic travel brings exotic diseases into our offices, GIDEON provides world-class consultation. It continues to be the best designed expert program I have seen for medical practice.”

GIDEON in previous incarnations has been reviewed in JAMA in the past:

2002: “GIDEON is the epitome of its genre. If you are a clinician having any contact with infectious diseases, working in a microbiology laboratory … the Global Infectious Disease and Epidemiology Network is worth examining. This important program deserves widespread attention.”

1997: “Anyone who has never used a good artificial intelligence program would do well to start at the top with GIDEON”

GIDEON Sign In